Article
Oncology
Hao Liu, Li-Hong Chen, Zhi-Hui Zhang, Ning Wang, Si-Hui Zhuang, Hao Chen, Jin Du, Li-Juan Pang, Yan Qi
Summary: This study reported two cases of small cell transformation of non-small cell lung cancer (NSCLC) after targeted therapy or immunotherapy. The transformation to small cell lung cancer is a potential mechanism of NSCLC resistance to targeted therapy or immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Lei Sun, Man Li, Ling Deng, Yuchun Niu, Yichun Tang, Yu Wang, Linlang Guo
Summary: This study demonstrates that MGA mutation can serve as a novel predictive biomarker for ICI response in non-squamous NSCLC, showing better efficacy and survival outcomes in related patients, associated with higher TMB, neoantigen load, and DNA damage repair deficiency.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Jiajia Song, Ling Bai, Jianzhao Zhai, Zhaodan Xin, Liting You, Yi Zhou, Juan Zhou, Binwu Ying
Summary: The frequency and proportion of ctDNA mutations are associated with therapeutic outcomes, and patients with lower mutation frequencies have better prognosis.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Jennifer W. Carlisle, Ticiana Leal
Summary: Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma that has limited effective treatments. Advances in DNA sequencing and whole transcriptomics have identified key subtypes, leading to the development of chemoimmunotherapy as the standard of care for advanced disease. Ongoing research is focused on incorporating immunotherapy into limited stage settings and exploring combination strategies with radiation.
Article
Immunology
Na Li, Jiahong Wang, Xianquan Zhan
Summary: This study identified two reliable immune-related gene signature models that were significantly associated with prognosis and tumor microenvironment cell infiltration in LUAD and LUSC, respectively. Evaluation of these models could help predict response to immunotherapy and guide immunotherapy strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Manuela Carvalheiro, Margarida Ferreira-Silva, Denys Holovanchuk, H. Susana Marinho, Joao Nuno Moreira, Helena Soares, M. Luisa Corvo, Maria Eugenia M. Cruz
Summary: This study evaluated the ability of antagonist G to improve the targeting and internalization of liposomal formulations to small cell lung carcinoma (SCLC) cell lines. The results showed that covalent attachment of antagonist G increased cellular association and internalization of liposomes via receptor-mediated and clathrin-dependent endocytosis. Biodistribution studies in mice demonstrated preferential lung accumulation of antagonist G-targeted liposomes, indicating their potential as delivery vectors for SCLC treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Oncology
Haiping Jiang, Yinan Wang, Hanlin Xu, Wei Lei, Xiaoyun Yu, Haiying Tian, Cong Meng, Xueying Wang, Zicheng Zhao, Xiangfeng Jin
Summary: This study identified multiple driver gene mutations in Chinese patients with non-small cell lung carcinoma, with EGFR mutations being the most common. The research also discovered new potentially pathogenic variants and frequent pathogenic variants. These findings provide valuable insights for guiding the treatment strategies for lung cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Xu Zhang, Yuxiang Wang, Linghua Meng
Summary: Esophageal cancer is a highly lethal disease with rapid progression and poor prognosis. The two major subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), have distinct risk factors and molecular characteristics. Although surgical and chemoradiotherapy approaches have been applied, molecularly targeted therapy for esophageal cancer is still in its early stages. Advances in large-scale next-generation sequencing have revealed genomic alterations in ESCC and EAC, providing insights into their roles in the development and progression of esophageal cancer. Potential therapeutic targets have been identified, and novel strategies are under development to combat this disease.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Oncology
Jin-Dong Li, Cheng-Yan Jin, Yan Zhang, Hang Guo, Guang-Lei Zhang, Chun-Guang Wang
Summary: This case report describes a patient with lung cancer who experienced histopathological transformation from squamous-cell carcinoma to large cell neuroendocrine carcinoma with a small fraction of small cell carcinoma.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Health Care Sciences & Services
Nina Pujol, Simon Heeke, Christophe Bontoux, Jacques Boutros, Marius Ilie, Veronique Hofman, Charles-Hugo Marquette, Paul Hofman, Jonathan Benzaquen
Summary: Molecular diagnosis of lung cancer is a constantly evolving field that requires repeated testing to establish accurate molecular diagnosis and track disease evolution. The emergence of next-generation sequencing (NGS) has greatly facilitated molecular profiling in lung cancer.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Nicholas McNamee, Ines Pires da Silva, Adnan Nagrial, Bo Gao
Summary: Small-cell lung cancer (SCLC) is an aggressive disease with limited treatment options and poor survival rates. While there have been significant advancements in the treatment of non-small cell lung cancer (NSCLC), SCLC has not seen the same level of progress. This is due, in part, to the complex and heterogeneous nature of SCLC tumors. This review explores the current treatment paradigm of SCLC, recent advances in immunotherapy, challenges in identifying predictive biomarkers, and potential future directions in SCLC treatment research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Baharia Mograbi, Simon Heeke, Paul Hofman
Summary: This review discusses the utilization of immunotherapy in the first-line treatment of NSCLC, focusing on the association between mutations in STK11/LKB1 and the lack of response to immunotherapy. It also highlights the potential directions and key points for future research in this area.
Review
Oncology
Jiajian Shi, Yuchen Chen, Chentai Peng, Linwu Kuang, Zitong Zhang, Yangkai Li, Kun Huang
Summary: Lung cancer has one of the highest incidence and mortality rates among all cancers worldwide. Non-small cell lung cancer (NSCLC), accounting for 85% of all lung cancer cases, is a major threat to human health. Recent advances in targeted therapies against driver mutations and epigenetic alterations have benefited NSCLC patients. Druggable driver mutations, including EGFR, KRAS, MET, HER2, ALK, ROS1, RET, and BRAF, have been identified in over a quarter of NSCLC patients. Highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been extensively studied and used in clinical treatments, leading to improved overall survival rates for NSCLC patients. However, drug resistance remains a challenge, and various approaches are being developed to overcome it, including inhibitors targeting new mutants and combination therapy with other pathway inhibitors. Epigenetics-based therapy is also emerging as a promising approach, as epigenetic regulators like histone deacetylases and non-coding RNA play crucial roles in cancer development and drug resistance. Combining epigenetics-based therapeutic strategies with targeted drugs has shown great clinical potential, with several agents targeting epigenetic changes currently under investigation in preclinical and clinical studies.
Review
Medicine, Research & Experimental
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Summary: Non-small cell lung cancer (NSCLC) is the most common and deadly malignancy of lung cancer; chemotherapy is gradually withdrawn from the stage of history due to its obvious side effects; researchers are now focusing on targeted drugs for the treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Oncology
Barbara Melosky, Paul Wheatley-Price, Rosalyn A. Juergens, Adrian Sacher, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B. Card, Quincy Chu
Summary: Lung cancer is a highly heterogeneous disease driven by well-characterized driver mutations, with rapid advances in molecular characterization leading to the development of novel therapeutics targeting various oncogenic alterations. Multiple new targeted treatment options have emerged, with promising outcomes leading to FDA approval for several novel agents in advanced NSCLC.
Review
Oncology
Byoung Chul Cho, Allison Simi, Joshua Sabari, Smruthi Vijayaraghavan, Sheri Moores, Alexander Spira
Summary: Substantial therapeutic advancements have been made in identifying and treating activating mutations in advanced non-small cell lung cancer (NSCLC). However, resistance to EGFR and MET inhibitors remains common with current targeted therapies. Amivantamab, a fully human bispecific antibody targeting EGFR and MET, has shown efficacy and safety in patients with advanced NSCLC and provides a diverse antitumor mechanism through its multiple potential mechanisms of action.
CLINICAL LUNG CANCER
(2023)
Article
Oncology
Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis
Summary: This study reports the final analysis from ASTRIS, the largest real-world study of osimertinib in patients with advanced/metastatic EGFR T790M NSCLC. The results demonstrate the clinical benefit and safety of osimertinib in this patient population.
Article
Oncology
Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L. Reckamp, Sunil Sharma, Hirak Der-Torossian, James G. Christensen, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Richard Chao, Geoffrey Shapiro
Summary: This phase I study determined the maximum tolerated dose, recommended phase II dose, and safety profile of glesatinib in patients with advanced or unresectable solid tumors. The study found that glesatinib had antitumor activity in patients with tumors harboring overexpression or amplification of MET and AXL, as well as MET-activating mutations or rearrangements. Based on the clinical activity, safety, and pharmacokinetic data, SDD 750 mg twice daily was selected as the preferred formulation and dose of glesatinib.
Article
Medicine, Research & Experimental
Win Lwin Thuya, Li Ren Kong, Nicholas L. Syn, Ling -Wen Ding, Esther Sok Hwee Cheow, Regina Tong Xin Wong, Tingting Wang, Robby Miguel Wen-Jing Goh, Hongyan Song, Migara K. Jayasinghe, Minh T. N. Le, Jian Cheng Hu, Wei-Peng Yong, Soo-Chin Lee, Andrea Li-Ann Wong, Gautam Sethi, Huynh The Hung, Paul Chi-Lui Ho, Jean-Paul Thiery, Siu Kwan Sze, Tiannan Guo, Ross A. Soo, Henry Yang, Yaw Chyn Lim, Lingzhi Wang, Boon-Cher Goh
Summary: This study reveals that the cargo protein FAM3C carried by tumor-released extracellular vesicles (EVs) can enhance the growth and metastatic potential of lung cancer cells. FAM3C interacts with RalA protein to activate the Src/Stat3 signaling pathway, promoting oncogenicity. This finding provides a new target for lung cancer therapy.
Article
Critical Care Medicine
Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip
Summary: After 3 years of follow-up, lorlatinib showed durable benefit over crizotinib in treatment-naive ALK-positive non-small-cell lung cancer patients, indicating the potential use of lorlatinib as a first-line treatment option.
LANCET RESPIRATORY MEDICINE
(2023)
Article
Oncology
Ryoung-Eun Ko, Jaehyeong Cho, Min-Kyue Shin, Sung Woo Oh, Yeonchan Seong, Jeongseok Jeon, Kyeongman Jeon, Soonmyung Paik, Joon Seok Lim, Sang Joon Shin, Joong Bae Ahn, Jong Hyuck Park, Seng Chan You, Han Sang Kim
Summary: This study presents a new machine learning-based mortality prediction model for critically ill cancer patients admitted to the intensive care unit. The model, called CanICU, shows high sensitivity and specificity and uses nine easily obtainable variables. It offers improved performance compared to current prognostic models and can help physicians allocate ICU care for cancer patients based on objective mortality risk.
Article
Multidisciplinary Sciences
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Summary: By sequencing circulating tumor DNA in patients from the FLAURA trial, this study identifies MET amplification and EGFR C797S mutation as the most frequent acquired resistance mechanisms to first-line osimertinib.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, Adrian Kee, Sen Hee Tay, Folefac Aminkeng, Yvonne Ang, Alvin S. C. Wong, Lavina D. Bharwani, Boon Cher Goh, Ross A. Soo
Summary: Primary resistance to immune checkpoint inhibitor (ICI) treatment is a common issue in patients with advanced non-small-cell lung cancer (NSCLC). In this study, we identified female gender, an elevated neutrophil-to-lymphocyte ratio (NLR) of >= 3 at 6 weeks, and a later line of immunotherapy treatment (>= 2 lines) as predictive factors for primary resistance to ICI monotherapy.
Article
Oncology
Kumar Prabhash, Daniel Shao Weng Tan, Ross A. Soo, Piyada Sitthideatphaiboon, Yuh Min Chen, Pei Jye Voon, Elisna Syahruddin, Sojung Chu, Reto Huggenberger, Byoung-Chul Cho
Summary: KINDLE-Asia evaluated treatment patterns and survival outcomes in patients with stage III non-small cell lung cancer in Asia, showing diverse treatment patterns and survival outcomes in the region. The high prevalence of EGFRm and PD-L1 expression suggests the need for expanding molecular testing in Asia.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Min Soo Joo, Kyoung-Ho Pyo, Jong-Moon Chung, Byoung Chul Cho
Summary: This paper investigates statistical techniques and AI-based methods for analyzing non-small cell lung cancer transcriptome data. The goal is to find essential biomarkers and classify carcinomas and cluster NSCLC subtypes. The methods are divided into three categories: statistical analysis, machine learning, and deep learning. The paper summarizes specific models and ensemble techniques used in NSCLC analysis, aiming to lay a foundation for advanced research by converging and linking the various analysis methods available.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Dongjin Seo, Han Sang Kim, Joong Bae Ahn, Yu Rang Park
Summary: This study aimed to evaluate the prognostic impact of initial status and trajectories of muscle and BMI on overall survival in colorectal cancer patients. The results indicated that the trajectories of muscle and BMI were related to overall survival, and increasing muscle mass was associated with better survival. Therefore, the changes in muscle and BMI can serve as important indicators for predicting survival in colorectal cancer patients.
JMIR PUBLIC HEALTH AND SURVEILLANCE
(2023)
Article
Biochemistry & Molecular Biology
Byoung Chul Cho, Dong-Wan Kim, Alexander I. Spira, Jorge E. Gomez, Eric B. Haura, Sang-We Kim, Rachel E. Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong-Seok Lee, Ji-Youn Han, Misako Nagasaka, Joshua K. Sabari, Sai-Hong Ignatius Ou, Patricia Lorenzini, Joshua M. Bauml, Joshua C. Curtin, Amy Roshak, Grace Gao, John Xie, Meena Thayu, Roland E. Knoblauch, Keunchil Park
Summary: This study evaluated the potential of combining amivantamab and lazertinib in patients with EGFR-mutated NSCLC. The results showed that this combination therapy had improved anti-tumor activity in some patients, with a safety profile similar to monotherapy.
Article
Cell Biology
Kyukwang Kim, Mooyoung Kim, Andrew J. Lee, Sang-Hyun Song, Jun-Kyu Kang, Junghyun Eom, Young-Joon Kim, Gyeong Hoon Kang, Jeong Mo Bae, Sunwoo Min, Yeonsoo Kim, Yoojoo Lim, Han Sang Kim, Tae -You Kim, Inkyung Jung
Summary: This study investigates the regulatory effect of non-coding large-scale structural variations (SVs) on proto-oncogene activation by profiling 3D cancer genome maps. The analysis reveals the establishment of de novo chromatin contacts that span multiple topologically associating domains (TADs) and the occurrence of super-enhancer (SE) hijacking and its clonal characteristics. The activation of oncogenes and increased drug resistance due to SE hijacking are validated using CRISPR-Cas9. This research provides insights into the regulatory principles of large-scale SVs in oncogene activation and their clinical implications.
Article
Oncology
Youngtaek Kim, Joon Yeon Hwang, Dong Kwon Kim, Kwangmin Na, Seul Lee, Sujeong Baek, Seong-san Kang, Seung Min Yang, Mi Hyun Kim, Heekyung Han, Chai Young Lee, Yu Jin Han, Min Hee Hong, Jii Bum Lee, Sun Min Lim, Byoung Chul Cho, Youngjoon Park, Kyoung-Ho Pyo
Summary: The expression of PLK4 is increased in lung adenocarcinoma tissues and is associated with poor prognosis and cell-proliferation-related pathways. Furthermore, PLK4 expression and its correlated pathways are upregulated in LUAD patients with TP53 mutations.
Article
Oncology
Jaekyung Cheon, Hyeyeong Kim, Han Sang Kim, Chang Gon Kim, Ilhwan Kim, Beodeul Kang, Chan Kim, Sanghoon Jung, Yeonjung Ha, Hong Jae Chon
Summary: This study analyzed the efficacy and safety of Ate/Bev treatment in 36 patients with Child-Pugh B advanced hepatocellular carcinoma. The results showed that compared to patients with Child-Pugh A, patients with Child-Pugh B had a higher frequency of severe adverse events. Although Ate/Bev treatment had limited clinical activity in patients with Child-Pugh B, careful evaluation and management of treatment response and adverse events are still necessary in this patient subgroup.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)